Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Hum Vaccin Immunother ; 15(9): 2195-2204, 2019.
Article in English | MEDLINE | ID: mdl-30427741

ABSTRACT

There is an unmet medical need for vaccines to prevent dengue. V180 is an investigational recombinant subunit vaccine that consists of truncated dengue envelope proteins (DEN-80E) for all 4 serotypes. Three dosage levels of the tetravalent DEN-80E antigens were assessed in a randomized, placebo-controlled, Phase I dose-escalation, first-in-human proof-of-principle trial in healthy, flavivirus-naïve adults in Australia (NCT01477580). The 9 V180 formulations that were assessed included either ISCOMATRIX™ adjuvant (2 dosage levels), aluminum-hydroxide adjuvant, or were unadjuvanted, and were compared to phosphate-buffered saline placebo. Volunteers received 3 injections of assigned product on a 0, 1, 2 month schedule, and were followed for safety through 1 year after the last injection. Antibody levels were assessed at 6 time-points: enrollment, 28 days after each injection, and 6 and 12 months Postdose 3 (PD3). Of the 98 randomized participants, 90 (92%) received all 3 injections; 83 (85%) completed 1-year follow-up. Immunogenicity was measured by a qualified Focus Reduction Neutralization Test with a 50% neutralization cutoff (FRNT50). All 6 V180 formulations with ISCOMATRIX™ adjuvant showed robust immunogenicity, while the 1 aluminum-adjuvanted and 2 unadjuvanted formulations were poorly immunogenic. Geometric mean antibody titers generally declined at 6 months and 1 year PD3. All 9 V180 formulations were generally well tolerated. Formulations with ISCOMATRIX™ adjuvant were associated with more adverse events than aluminum-adjuvanted or unadjuvanted formulations.


Subject(s)
Dengue Vaccines/immunology , Dengue/prevention & control , Immunogenicity, Vaccine , Adjuvants, Immunologic/administration & dosage , Adolescent , Adult , Antibodies, Neutralizing/blood , Antibodies, Neutralizing/immunology , Antibodies, Viral/blood , Antibodies, Viral/immunology , Dengue Vaccines/administration & dosage , Dengue Virus , Drug Compounding , Female , Humans , Immunization Schedule , Male , Middle Aged , Neutralization Tests , Proof of Concept Study , Vaccines, Subunit/administration & dosage , Vaccines, Subunit/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology , Young Adult
2.
Hum Vaccin Immunother ; 12(8): 2135-2141, 2016 08 02.
Article in English | MEDLINE | ID: mdl-27002793

ABSTRACT

PNEUMOVAX™ 23, a 23-valent polysaccharide pneumococcal vaccine (PPV23), covers 65% to 91% of the isolates recovered from adult cases of invasive pneumococcal disease. Several studies have demonstrated that pneumococcal serotypes 31, 11A, 35F, 17F, 3, 16F, 19F, 15B, and 10A are associated with higher case-fatality or meningitis rates than other pneumococcal serotypes. This study (U05-PnPS-403; EudraCT: 2008-003648-12) evaluated the immune response followings administration of PPV23 for 4 of these serotypes (10A, 11A, 15B, and 17F), that are included in PPV23 but not in licensed pneumococcal conjugate vaccines. Serotype-specific IgG geometric mean concentrations (GMCs) and geometric mean fold-rises (GMFRs) for these 4 serotypes were measured by a validated enzyme-linked immunosorbent assay (ELISA) in 104 subjects >50 y of age who were enrolled in a study evaluating the safety and immunogenicity of a single-dose of PPV23. At 1 month post-vaccination, GMCs for serotypes10A, 11A, 15B and 17F were 6.5, 4.3, 14.7, and 5.1 µg/mL, respectively. GMFRs from baseline were 9.0, 4.5, 8.4, and 11.5, respectively. The percentages of subjects achieving >2-fold increases in IgG GMCs between pre-vaccination and 1 month post-vaccination were 90%, 85%, 88% and 89%, respectively. In conclusion, PPV23 induces a robust immune response in adults to pneumococcal serotypes 10A, 11A, 15B, and 17F, which have been associated with elevated case-fatality or meningitis rates.


Subject(s)
Antibody Formation , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/administration & dosage , Pneumococcal Vaccines/immunology , Aged , Aged, 80 and over , Antibodies, Bacterial/blood , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin G/blood , Male , Middle Aged , Pneumococcal Infections/microbiology , Serogroup , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/immunology , Treatment Outcome
3.
Vaccine ; 33(50): 7126-34, 2015 Dec 10.
Article in English | MEDLINE | ID: mdl-26458804

ABSTRACT

This review focuses on a dengue virus (DENV) vaccine candidate based on a recombinant subunit approach which targets the DENV envelope glycoprotein (E). Truncated versions of E consisting of the N-terminal portion of E (DEN-80E) have been expressed recombinantly in the Drosophila S2 expression system and shown to have native-like conformation. Preclinical studies demonstrate that formulations containing tetravalent DEN-80E adjuvanted with ISCOMATRIX™ adjuvant induce high titer virus neutralizing antibodies and IFN-γ producing T cells in flavivirus-naïve non-human primates. The preclinical data further suggest that administration of such formulations on a 0, 1, 6 month schedule may result in higher maximum virus neutralizing antibody titers and better durability of those titers compared to administration on a 0, 1, 2 month schedule. In addition, the virus neutralizing antibody titers induced by adjuvanted tetravalent DEN-80E compare favorably to the titers induced by a tetravalent live virus comparator. Furthermore, DEN-80E was demonstrated to be able to boost virus neutralizing antibody titers in macaques that have had a prior DENV exposure. A monovalent version of the vaccine candidate, DEN1-80E, was formulated with Alhydrogel™ and studied in a proof-of-principle Phase I clinical trial by Hawaii Biotech, Inc. (NCT00936429). The clinical trial results demonstrate that both the 10 µg and 50 µg formulations of DEN1-80E with 1.25 mg of elemental aluminum were immunogenic when administered in a 3-injection series (0, 1, 2 months) to healthy, flavivirus-naïve adults. The vaccine formulations induced DENV-1 neutralizing antibodies in the majority of subjects, although the titers in most subjects were modest and waned over time. Both the 10 µg DEN1-80E and the 50 µg DEN1-80E formulations with Alhydrogel™ were generally well tolerated.


Subject(s)
Clinical Trials, Phase I as Topic , Dengue Vaccines/administration & dosage , Dengue Vaccines/immunology , Dengue/prevention & control , Drug Evaluation, Preclinical , Adjuvants, Immunologic/administration & dosage , Aluminum Hydroxide/administration & dosage , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Cholesterol/administration & dosage , Dengue/epidemiology , Dengue Vaccines/genetics , Dengue Vaccines/isolation & purification , Drug Combinations , Humans , Immunization Schedule , Interferon-gamma/metabolism , Macaca , Phospholipids/administration & dosage , Saponins/administration & dosage , T-Lymphocytes/immunology , Vaccines, Subunit/administration & dosage , Vaccines, Subunit/genetics , Vaccines, Subunit/immunology , Vaccines, Subunit/isolation & purification , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccines, Synthetic/isolation & purification
4.
J Clin Virol ; 64: 153-9, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25453329

ABSTRACT

Dengue causes more human morbidity globally than any other vector-borne viral disease. Recent research has led to improved epidemiological methods that predict disease burden and factors involved in transmission, a better understanding of immune responses in infection, and enhanced animal models. In addition, a number of control measures, including preventative vaccines, are in clinical trials. However, significant gaps remain, including the need for better surveillance in large parts of the world, methods to predict which individuals will develop severe disease, and immunologic correlates of protection against dengue illness. During the next decade, dengue will likely expand its geographic reach and become an increasing burden on health resources in affected areas. Licensed vaccines and antiviral agents are needed in order to effectively control dengue and limit disease.


Subject(s)
Dengue/epidemiology , Dengue/prevention & control , Disease Management , Animals , Antiviral Agents/therapeutic use , Dengue/immunology , Dengue/virology , Dengue Vaccines/immunology , Humans
5.
J Infect Dis ; 208(9): 1375-85, 2013 Nov 01.
Article in English | MEDLINE | ID: mdl-23908479

ABSTRACT

BACKGROUND: Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) were assessed in immunocompromised adults. METHODS: In a randomized, double-blind, placebo-controlled, multicenter study, 4 doses ZVHT or placebo were administered approximately 30 days apart to adults with either solid tumor malignancy (STM); hematologic malignancy (HM); human immunodeficiency virus (HIV) with CD4(+) ≤200; autologous hematopoietic stem-cell transplant (HCT) or allogeneic-HCT recipients. Varicella-zoster virus (VZV) T-cell responses by interferon-γ enzyme-linked immunospot (IFN-γ ELISPOT) and VZV antibody concentrations by glycoprotein enzyme-linked immunosorbent assay (gpELISA) were measured at baseline and approximately 28 days after each dose. RESULTS: No safety signals were found in any group. IFN-γ ELISPOT geometric mean fold rises (GMFR) after dose 4 in STM, HM, HIV, and autologous-HCT patients were 3.00 (P < .0001), 2.23 (P = .004), 1.76 (P = .026), and 9.01 (P = NA), respectively. Similarly, antibody GMFR were 2.35 (P < .0001), 1.28 (P = .003), 1.37 (P = .017), and 0.90 (P = NA), respectively. T-cell and antibody responses were poor after 4 doses of ZVHT in allogeneic-HCT patients. CONCLUSION: ZVHT was generally safe and immunogenic through 28 days post-dose 4 in adults with STM, HM, and HIV. Autologous-HCT but not allogeneic-HCT patients had a rise in T-cell response; antibody responses were not increased in either HCT population. Study identification. V212-002 Clinical Trials Registration. NCT00535236.


Subject(s)
HIV Infections/immunology , Herpes Zoster Vaccine/adverse effects , Herpes Zoster/prevention & control , Immunocompromised Host , Neoplasms/immunology , Adult , Aged , Aged, 80 and over , Double-Blind Method , Female , Hematopoietic Stem Cell Transplantation , Herpes Zoster Vaccine/immunology , Humans , Male , Middle Aged , Neoplasms/therapy , Treatment Outcome , Vaccination , Vaccines, Attenuated/adverse effects , Vaccines, Attenuated/immunology , Young Adult
6.
Vaccine ; 30(48): 6918-26, 2012 Nov 06.
Article in English | MEDLINE | ID: mdl-22959986

ABSTRACT

M-M-R™II (measles, mumps, and rubella virus vaccine live; Merck, Sharp, & Dohme Corp.) is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals ≥ 12 months of age. Before the vaccine era, these viruses infected most exposed individuals, with subsequent morbidity and mortality. One of the greatest achievements of public health has been to eliminate these 3 diseases in large geographic areas. The safety profile of M-M-R™II is described using data from routine global postmarketing surveillance. Postmarketing surveillance has limitations (including incomplete reporting of case data), but allows collection of real-world information on large numbers of individuals, who may have concurrent medical problems excluding them from clinical trials. It can also identify rare adverse experiences (AEs). Over its 32-year history, ≈ 575 million doses of M-M-R™II have been distributed worldwide, with 17,536 AEs voluntarily reported for an overall rate of 30.5 AEs/1,000,000 doses distributed. This review provides evidence that the vaccine is safe and well-tolerated.


Subject(s)
Measles-Mumps-Rubella Vaccine/adverse effects , Measles-Mumps-Rubella Vaccine/immunology , Measles/prevention & control , Mumps/prevention & control , Product Surveillance, Postmarketing , Rubella/prevention & control , Drug-Related Side Effects and Adverse Reactions/epidemiology , Humans , Measles/epidemiology , Measles-Mumps-Rubella Vaccine/administration & dosage , Mumps/epidemiology , Rubella/epidemiology
7.
Vaccine ; 30(30): 4435-44, 2012 Jun 22.
Article in English | MEDLINE | ID: mdl-22542818

ABSTRACT

Since publication of a 1997 review of the immunogenicity and safety data for pneumococcal polysaccharide vaccines (PPSVs), dozens of additional studies have been published, involving larger cohorts, longer observation periods, and more specific assays. Additionally, a 13-valent pneumococcal conjugate vaccine (PCV) has been licensed for adults. This paper reviews adult studies assessing antibody persistence for ≥ 3 years after pneumococcal vaccination, and adult studies of immunogenicity and safety after revaccination. This review emphasizes the currently registered PPSV23 formulations containing 25-µg polysaccharide per serotype, for which far more long-term data are available. Broadly, IgG and functional antibody levels after PPSV23 in adults persist above concentrations in unvaccinated adults for at least 5-10 years in most studies. The few exceptions involve populations of non-ambulatory adults or those with confounding host-factor issues. Revaccination with PPSV23 5-10 years after a previous dose consistently and substantially increases both IgG and functional antibody levels. There is an inverse association between circulating antibody level just before primary or revaccination and subsequent antibody increase. Although injection-site reactions (e.g., pain, swelling, redness) were reported more commonly after PPSV23 revaccination than after primary vaccination in most studies, these reactions typically resolved within 5 days. We interpret the contemporary literature as supporting pneumococcal revaccination as a means to sustain anti-pneumococcal antibodies at levels greater than among unvaccinated adults. PPSV23 is a broad-spectrum public-health tool to help prevent serious pneumococcal diseases across the adult lifespan.


Subject(s)
Antibodies, Bacterial/blood , Immunization, Secondary , Pneumococcal Vaccines/immunology , Adult , Antibody Formation , Humans , Immunoglobulin G/blood , Pneumococcal Vaccines/adverse effects , Time Factors
8.
Hum Vaccin ; 7(9): 919-28, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21860256

ABSTRACT

In a study of older adults, first and second doses of 23-valent pneumococcal polysaccharide vaccine (PN23) induced IgG increases for all 8 vaccine serotypes tested. Participants (N=143, mean age 76 years) were re-enrolled to study antibody levels after ten years, and safety and immunogenicity of another PN23 dose. Ten years after first or second doses, mean IgG concentrations exceeded vaccine-naïve levels for 7 of 8 serotypes tested. Second and third doses administered at this time were generally well tolerated and were immunogenic, inducing similar postvaccination levels. Immunogenicity is preserved after multiple PN23 doses without evidence of a lower than expected immune response (i.e., without hyporesponsiveness).


Subject(s)
Antibodies, Bacterial/blood , Immunization Schedule , Immunoglobulin G/blood , Pneumococcal Vaccines/administration & dosage , Pneumonia, Pneumococcal/prevention & control , Age Factors , Aged , Aged, 80 and over , Antibodies, Bacterial/immunology , Female , Follow-Up Studies , Humans , Immunoglobulin G/immunology , Male , Middle Aged , Pneumococcal Vaccines/adverse effects , Pneumococcal Vaccines/immunology , Pneumonia, Pneumococcal/immunology , Time Factors
10.
J Infect Dis ; 201(4): 525-33, 2010 Feb 15.
Article in English | MEDLINE | ID: mdl-20088694

ABSTRACT

BACKGROUND: Older adults are at high risk of developing invasive pneumococcal disease, but the optimal timing and number of vaccine doses needed to prevent disease among this group are unknown. We compared revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23) with primary vaccination for eliciting initial and persistent functional antibody responses. METHODS: Subjects aged > or = 65 years were enrolled. Functional (opsonic) and total immunoglobulin (Ig) G antibody levels were measured following either PN23 primary vaccination (n = 60) or revaccination 3-5 years after receiving a first PN23 vaccination (n = 60). Antibody against vaccine serotypes 4, 14, and 23F was measured at prevaccination (day 0), 30 days after vaccination, and 5 years after vaccination. RESULTS: By day 30, both primary vaccination and revaccination induced significant increases in opsonic and IgG antibody levels. Day 30 levels following revaccination were slightly lower but not significantly different than those after primary vaccination. Year 5 levels were similar in both groups and remained significantly higher than prevaccination levels for primary vaccination subjects. There was good agreement between postvaccination opsonic and IgG antibody levels. CONCLUSIONS: Revaccination of older adults with PN23 was comparable to primary vaccination for inducing elevated and persistent functional and IgG antibody responses.


Subject(s)
Antibodies, Bacterial/immunology , Immunization, Secondary , Immunoglobulin G/immunology , Pneumococcal Vaccines/immunology , Age Factors , Aged , Aged, 80 and over , Antibodies, Bacterial/blood , Antibodies, Bacterial/metabolism , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin G/blood , Immunoglobulin G/metabolism , Linear Models , Longitudinal Studies , Male , Pneumococcal Vaccines/administration & dosage
11.
J Med Virol ; 81(7): 1310-22, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19475609

ABSTRACT

A real-time PCR assay was developed to identify varicella-zoster virus (VZV) and herpes simplex virus (HSV) DNA in clinical specimens from subjects with suspected herpes zoster (HZ; shingles). Three sets of primers and probes were used in separate PCR reactions to detect and discriminate among wild-type VZV (VZV-WT), Oka vaccine strain VZV (VZV-Oka), and HSV DNA, and the reaction for each virus DNA was multiplexed with primers and probe specific for the human beta-globin gene to assess specimen adequacy. Discrimination of all VZV-WT strains, including Japanese isolates and the Oka parent strain, from VZV-Oka was based upon a single nucleotide polymorphism at position 106262 in ORF 62, resulting in preferential amplification by the homologous primer pair. The assay was highly sensitive and specific for the target virus DNA, and no cross-reactions were detected with any other infectious agent. With the PCR assay as the gold standard, the sensitivity of virus culture was 53% for VZV and 77% for HSV. There was 92% agreement between the clinical diagnosis of HZ by the Clinical Evaluation Committee and the PCR assay results.


Subject(s)
Chickenpox Vaccine , Herpes Simplex Virus Vaccines , Herpesvirus 3, Human/classification , Herpesvirus 3, Human/genetics , Polymerase Chain Reaction/methods , Simplexvirus/classification , Simplexvirus/genetics , DNA Primers , Diagnosis, Differential , Herpes Simplex/diagnosis , Herpes Zoster/diagnosis , Herpesvirus 3, Human/isolation & purification , Humans , Polymerase Chain Reaction/standards , Polymorphism, Single Nucleotide , Reference Standards , Sensitivity and Specificity , Simplexvirus/isolation & purification , Vaccines , beta-Globins/genetics
12.
Pediatr Infect Dis J ; 21(10): 978-9, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12400528

ABSTRACT

Two injections of tetravalent (Groups A, C, Y and W-135) meningococcal polysaccharide vaccine conjugated to diphtheria were given to 30 toddlers at dosages of 1, 4 and 10 microg/ml polysaccharide of each serogroup. Reactogenicity was acceptable at all dosages. The 4-microg/ml dose appears to be immunologically optimal.


Subject(s)
Antigens, Bacterial/analysis , Immunity/physiology , Meningococcal Infections/prevention & control , Meningococcal Vaccines/administration & dosage , Vaccination/methods , Child, Preschool , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunization Schedule , Infant , Male , Polysaccharides, Bacterial , Safety , Sensitivity and Specificity , Treatment Outcome , Vaccines, Conjugate
SELECTION OF CITATIONS
SEARCH DETAIL
...